Switching UC treatments while managing a career and home life can be a major challenge. Here’s how to navigate work logistics ...

What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Ulcerative colitis treatment drug Omvoh, from Eli Lilly, was linked to sustained clinical remission after 4 years, according to new trial data. Image credit: Plexi Images/GHI/UCG/Universal Images ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

You and your doctor already have a variety of treatment options available for ulcerative colitis (UC), but science marches on, with the pharmaceutical industry close behind. Dozens of novel therapies ...

Patients with active ulcerative colitis may be able to reduce symptoms and achieve remission by taking a plant-based treatment combining the herbal compounds curcumin and qingdai, preliminary results ...

Our gut is the key to much of our body's overall health, which is why diseases like ulcerative colitis can be so detrimental. Ulcerative colitis is one of the most common inflammatory bowel diseases.

Living with ulcerative colitis means navigating a complex and often unpredictable digestive condition that impacts daily life in profound ways. This inflammatory bowel disease affects approximately 1 ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

It is estimated that more than 5 million people worldwide suffer from ulcerative colitis, a chronic inflammation of the colon that often progresses in stages whose causes have not yet been fully ...

Female UC patients were 11% less likely to receive immunomodulator therapy compared to males. Women experienced 41% higher rates of UC-related hospitalizations than men. No significant sex-based ...